ID: ALA315200

Max Phase: Preclinical

Molecular Formula: C26H22ClN5O5

Molecular Weight: 519.95

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NC(=O)N1CCN(C(=O)CN2C(=O)C(=O)c3cc(Cl)ccc32)CC1)Nc1cccc2ccccc12

Standard InChI:  InChI=1S/C26H22ClN5O5/c27-17-8-9-21-19(14-17)23(34)24(35)32(21)15-22(33)30-10-12-31(13-11-30)26(37)29-25(36)28-20-7-3-5-16-4-1-2-6-18(16)20/h1-9,14H,10-13,15H2,(H2,28,29,36,37)

Standard InChI Key:  IMBBHWNCXBMHDG-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 519.95

Molecular Weight (Monoisotopic): 519.1309

AlogP: 3.11

#Rotatable Bonds: 3

Polar Surface Area: 119.13

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.96

CX Basic pKa:

CX LogP: 2.16

CX LogD: 2.16

Aromatic Rings: 3

Heavy Atoms: 37

QED Weighted: 0.52

Np Likeness Score: -1.49

References

1. Shuttleworth SJ, Nasturica D, Gervais C, Siddiqui MA, Rando RF, Lee N..  (2000)  Parallel synthesis of isatin-based serine protease inhibitors.,  10  (22): [PMID:11086715] [10.1016/s0960-894x(00)00523-0]

Source

Source(1):

• Scientific Literature